Results 1 to 10 of about 126,887 (307)

Combination immunotherapy with anti-PD-L1 antibody and depletion of regulatory T cells during acute viral infections results in improved virus control but lethal immunopathology [PDF]

, 2020
Combination immunotherapy (CIT) is currently applied as a treatment for different cancers and is proposed as a cure strategy for chronic viral infections. Whether such therapies are efficient during an acute infection remains elusive.
Akhmetzyanova, Ilseyar [u.v.m.], David, Paul David, Drabczyk-Pluta, Malgorzata, Gruber, Achim D., Honke, Nadine, Kershaw, Olivia, Knuschke, Torben, Megger, Dominik A., Pastille, Eva, Werner, Tanja   +9 more
core   +1 more source

Immune Checkpoint Blockade Improves Chemotherapy in the PyMT Mammary Carcinoma Mouse Model

Frontiers in Oncology, 2020
Despite the success of immune checkpoint blockade in cancer, the number of patients that benefit from this revolutionary treatment option remains low.
Evelyn Sirait-Fischer, Catherine Olesch, Annika F. Fink, Matthias Berkefeld, Arnaud Huard, Tobias Schmid, Kazuhiko Takeda, Bernhard Brüne, Bernhard Brüne, Bernhard Brüne, Bernhard Brüne, Andreas Weigert, Andreas Weigert, Andreas Weigert   +13 more
doaj   +1 more source

PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma

Cells, 2021
The dependence of cancer on an immunotolerant tumor microenvironment (TME) is well established. Immunotherapies that overcome tumor-induced immune suppression have been central to recent advancements in oncology.
Joshua W. D. Tobin, Karolina Bednarska, Ashlea Campbell, Colm Keane   +3 more
doaj   +1 more source

The Evolving Role of CD8+CD28- Immunosenescent T Cells in Cancer Immunology [PDF]

, 2019
Functional, tumor-specific CD8+ cytotoxic T lymphocytes drive the adaptive immune response to cancer. Thus, induction of their activity is the ultimate aim of all immunotherapies.
Dey, Mahua, Fetcko, Kaleigh, Henriquez, Mario, Huff, Wei X., Kwon, Jae Hyun   +4 more
core   +1 more source

Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy [PDF]

, 2017
Immune checkpoint factors, such as programmed cell death protein-1/2 (PD-1, PD-2) or cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) receptors, are targets for monoclonal antibodies (MAbs) developed for cancer immunotherapy.
Mai, Antonello, Mazzone, Roberta, Valente, Sergio, Zwergel, Clemens   +3 more
core   +1 more source

Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma.

PLoS ONE, 2019
We aimed to explore whether the combination of intradermal DNA vaccination, to boost immune response against melanoma antigens, and immune checkpoint blockade, to alleviate immunosuppression, improves antitumor effectiveness in a murine B16F10 melanoma ...
Spela Kos, Alessandra Lopes, Veronique Preat, Maja Cemazar, Ursa Lampreht Tratar, Bernard Ucakar, Kevin Vanvarenberg, Gregor Sersa, Gaelle Vandermeulen   +8 more
doaj   +1 more source

Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer

Neoplasia: An International Journal for Oncology Research, 2019
Immune checkpoint inhibitors have shown clinical benefit in several cancer entities including metastatic microsatellite instable colorectal carcinomas. However, for the majority of metastatic colorectal carcinomas the potential and limitations of immune ...
E Fiegle, D Doleschel, S Koletnik, A Rix, R Weiskirchen, E Borkham-Kamphorst, F Kiessling, W Lederle   +7 more
doaj   +1 more source

The Role of Immune Checkpoint Molecules on Macrophages in Cancer, Infection, and Autoimmune Pathologies

Frontiers in Immunology, 2022
Immune checkpoint inhibitors have revolutionized immunotherapy against various cancers over the last decade. The use of checkpoint inhibitors results in remarkable re-activation of patients’ immune system, but is also associated with significant adverse ...
Victoria C. Brom, Christof Burger, Dieter C. Wirtz, Frank A. Schildberg   +3 more
doaj   +1 more source

Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis [PDF]

, 2018
The research leading to these results received funding from the Obra Social “la Caixa” (to ME), the Cellex Foundation (to ME), the European Union's Horizon 2020 research and innovation programme under grant agreement No 727264 Epipharm (to ME), the 2015 ...
Calleja Cervantes, M. E., Duruisseaux, M., Fernández Fernández, Agustín, Fernández Fraga, Mario, Martínez Cardús, A.   +4 more
core   +1 more source

Improving cancer immunotherapy via co-delivering checkpoint blockade and thrombospondin-1 downregulator

Acta Pharmaceutica Sinica B, 2023
The use of checkpoint-blockade antibodies is still restricted in several malignancies due to the modest efficacy, despite considerable success in anti-tumor immunotherapy.
Qingqing Xiao, Xiaotong Li, Chang Liu, Yuxin Jiang, Yonglong He, Wanting Zhang, Helena S. Azevedo, Wei Wu, Yuanzheng Xia, Wei He   +9 more
doaj   +1 more source